Since the drug regimen for breast cancer patients is highly determined by the tumor molecular subtype, we next analyzed the correlation between high NSMCE2 gene expression levels with response to chemotherapy for each ER + PR + , HER2 + or TN tumor subtypes. The gene discussed is ERBB2; the disease is breast cancer.